Myocardial Revascularization
17
0
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 17 trials
100.0%
+13.5% vs benchmark
24%
4 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (17)
Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization
Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization
Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery
Nursing Intervention for Adaptation After Myocardial Revascularization
Disease Characteristics of R-CAD
FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease
Interventional Effects on Myocardial Revascularization Post-surgical Patients
The FAST OCT Study
FANTOM ENCORE Sirolimus-eluting Bioresorbable Scaffold for Treatment of De-novo CAD: the ENCORE-I Study
Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction
Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention
Spinal Anesthesia Associated With General Anesthesia in Coronary Artery Bypass
Stem Cell Therapy as Adjunct to Revascularization
Coronary Artery Bypass Grafting: Factors Related to Late Events and Saphenous Graft Patency
MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)
Revascularization in Heart Failure Trial - REHEAT 2
Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study)